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Abstract 
RATIONALE: RAS-RAF-MEK-ERK pathway has been considered a promising target for anticancer therapy. However, tumor cells 
may develop resistance against such drugs via hyperactivation of N-Ras, which explains why novel therapeut-ic approaches. In this 
sense, the Institute Curie- Université Pierre et Marie Curie (Paris 6) designed peptides in order to disturb Ras/Raf interaction which 
showed pro-apoptotic properties. These peptides were patented as WO2015001045 A2 (PCT/EP2014/064243)5.  
OBJECTIVE: In order to check the anti-tumoral action of WO2015001045 A2 peptides in a very aggressive BALB/c mice 
spontaneous leukemia called LB, we performed the present study.  
METHOD & RESULTS: 50 BALB/c mice inoculated with 106 LB tumor cells were randomly assigned either to control (placebo) or 
treatment group (that daily received 3 mg of peptide per kg of mice) during 30 days. By day 15 only 24% of the control group was 
alive vs. 100% of the treatment group. The average survival in treated group was 20,27 days while in control group the mean survival 
was 15,48 days. Either bone marrow, spleen or axillary nodes demonstrated a higher level of malignant T cell presence compare 
with treated group (89,78% ; 95,64% & 77,68% versus 72,45%, 80,23% & 63.44% respectively for each organ inspected.  
DISCUSSION: Our study demonstrated an improvement in survival curves in mice model affected by spontaneous T lymphoid 
leukemia when peptides WO2015001045 A2 were used. These peptides might be a valid option to become part of the therapeutic 
armory for malignant lymphoproliferative diseases control. 
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Introduction 
Ras is a GTPase family that consists of four highly 
related members: K-Ras 4A, K-Ras 4B, H-Ras and N-
Ras. These proteins are normally located at the inner 
leaflet of the plasma membrane, where they are involved 
in the signal transduction through interaction with multiple 
partners/ effectors. Ras functions as a switch between the 
GTP-bound active form and the GDP-bound inactive form. 
Active Ras binds to one of their multiple effectors, Raf 
serine/ threonine kinase (c-Raf or B-Raf), requires the 
interaction with Ras-GTP and induces their translocation 
to the plasma membrane where Ras is fully activated 
[1,2]. Ras/ Raf/ Mek/ Erk signal transduction pathway 
regulates cell cycle progression and apoptosis in diverse 
types of cells including malignant lines. This pathway can 
induce events associated with cell proliferation and cell 
cycle arrest, regulating multiple cellular processes 
including cell survival, growth, and differentiation. 
Following activation via association to GTP, Ras triggers 
three primary effectors, Raf, PI3K, and Ral-GDS. The 
three human Ras genes (H, K, and N) encode four highly 
related proteins. On the other hand, Raf (A, B and C) is a 
family of three protein serine/ threonine kinases that 
participate in several signaling cascades, that regulate a 
variety of processes like apoptosis, cell cycle progression, 
differentiation, proliferation and transformation to the 
cancerous state.  
Ras mutations occur in 15-30% of all human 
cancers while Raf mutations may also occur in different 
percentages depending of the type of cancer (B-Raf 
mutations are present in 30-60% of the melanomas, 30-
50% of the thyroid cancers, and 5-20% of the colorectal 
cancers) [1]. Certainly, the Ras and Raf mutations 
mentioned do not indicate all genes since these 
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superfamilies are composed of more than 150 distinct 
cellular members [2,3].   
Hence, Ras-Raf-Mek-Erk pathway has been 
considered a promising target for anticancer therapy 
[4,5]. B-Raf-inhibitors such as PLX4032 molecules are 
presently under investigation in clinical trials. However, 
there are also first hints that the tumor cells may develop 
resistance against such drugs via hyperactivation of N-
Ras [6], which defines a still persisting demand for novel 
targeted therapeutic approaches. In this sense, Institute 
Curie-Université Pierre et Marie Curie (Paris 6) in France, 
mapped the binding sites of K-Ras to B-Raf and designed 
peptides in order to disturb Ras/ Raf interaction, which 
showed pro-apoptotic properties. These peptides were 
patented as WO2015001045 A2 (PCT/ EP2014/ 064243) 
[7]. Thus, the invention provides a chimeric peptide 
capable of cell penetration and with pro-apoptotic 
properties. 
These peptides have demonstrated activity in 
several cancer lines like Lymphoma, B-Chronic Lymphoid 
Leukemia [8]. However, all these lines are based on 
human cancer cells transferred to mice, and because of 
that, immunity could have played a role in obtaining the 
favorable outcomes and therefore be biasing our results 
[9].   
In order to avoid an immunity role of 
WO2015001045 A2 (PCT/ EP2014/ 064243) peptides 
results, we identified a non-immunogenic leukemia mice 
model that may confirm that the apoptotic effect of 
peptides is the main mechanism for anti-cancer outcomes 
[9]. This lineage is called “LB” leukemia, which is a T-
lymphoid leukemia that arose spontaneously in a 6-
month-old BALB/ c male. Its immune-phenotype shows 
CD3-, CD25+, CD8+, CD4-, gp70-, J22d.2+, MHC class I 
+, and MHC class II – and TCRαβ negative antigens. It is 
maintained by subcutaneous (s.c.) serial passages in 
syngeneic mice and is usually used after 80 passages. It 
grows to a large size, infiltrating lymph nodes, spleen, and 
liver [10].     
LB is an extremely aggressive tumor that kills 
100% of the specimens treated after 30 days of 106 cells 
inoculation (average latency to death, 22 days). It is 
enough to inject 103 viable tumor cells to give a 50% 
probability of lethality (LD50) [10].   
To determine whether active viral replication was 
involved, one-month-old BALB/ c mice were inoculated 
intra-peritoneal with acellular extracts of LB and none of 
the specimens developed leukemia over a year of 
observation. Hence, since this leukemia is considered a 
non-immunogenic, non-viral induced tumor model [9,10], 
these features makes it ideal to develop an in vivo assay 
by using peptides as tools to regulate the apoptotic 
process; targeting proteins involved in that cell function.  
For all these reasons, LB lineage spontaneously 
emerged in BALB/ c mice and has become the ideal cell 
model to determine the true anti-tumoral action of 
WO2015001045 A2 (PCT/ EP2014/ 064243) peptides. 
Methods 
We started an experimental procedure based on 
LB tumor cells intra-peritoneal (i.p.) implanted in 50 BALB/ 
c mice. Tumor inoculums concentrations were 106 LB 
cells in all cases. 100% of the specimens inoculated 
finally developed tumor.  
Groups of treatment: the 50 BALB/ c mice 
selected for the experience were randomly divided into 
two groups: Group A: “Control group” that received i.p. 
placebo from day 5 until day 30 and Group B: “Treatment 
group” that received 3 mg of peptide per kg of mice, (12 ul 
of peptide diluted with 138 ul of normal saline for 20 gram 
mice) once a day between the 5th to 30th day of the assay. 
During the follow up period included, peptide or placebo 
were daily administrated until day 30 or until the mice’ 
death.  
Tumor burden anatomopathological analysis: 
after the specimen was sacrificed, samples of femoral 
bone marrow, spleen and axillary lymph nodes were 
obtained. All the samples were submitted to a microscopy 
analysis to detect changes in tissues & cells structure and 
to determinate the degree of leukemia infiltration.  
Apoptosis analysis: These 2 specimens were 
removed from the initial group of 52 mice, to perform the 
apoptosis analysis. They were not part of the general 
analysis of the survival study but were injected with LB 
leukemia in the same manner and on the same day as the 
rest of the mice. One of these two specimens was left 
untreated while the other mouse was injected with 3mg of 
peptide daily from the 5th day for 5 days and then 
sacrificed for the apoptosis analysis in the axillary nodes, 
bone marrow and spleen by TUNEL technique - TMR 
death detection kit (Roche). 
Survival analysis: mice status (alive/ dead) was 
checked twice a day. Overall survival analysis was 
performed at the end by Kaplan Meir method.  
Results 
All mice from the control group were dead by the 
23rd day (average survival 15, 48 days). By day 15, only 
24% of the group was alive, while all the mice from the 
intervention group were still living (Table 1).  
Although no mice in the treatment group was 
alive by the end of the experience (day 30), the average 
survival of the treated group was of 20, 27 days (range 
16-28 days), while in the control group, the mean survival 
was of 15, 48 days (range 11-23) (Fig. 1). 
The tumor mass estimation was performed after 
the specimen was sacrificed at day 30. Either bone 
marrow, spleen or axillary nodes demonstrated a higher 
level of malignant T cell presence compared to the treated 
group (89,78%; 95,64% & 77,68% versus 72,45%, 
80,23% & 63.44% respectively, for each organ inspected). 
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Table 1. Survival analysis 
Survival follow up 
 
  
Control  % 
Survival n (Alive) 
Treated % 
Survival n (Vivos) 
1 100 25 100 25 
2 100 25 100 25 
3 100 25 100 25 
4 100 25 100 25 
5 100 25 100 25 
6 100 25 100 25 
7 100 25 100 25 
8 100 25 100 25 
9 100 25 100 25 
10 100 25 100 25 
11 96 24 100 25 
12 92 23 100 25 
13 88 22 100 25 
14 84 21 100 25 
15 76 19 100 25 
16 76 19 96 24 
17 72 18 92 23 
18 64 16 92 23 
19 52 13 88 22 
20 36 9 88 22 
21 36 9 84 21 
22 16 4 80 20 
23 8 2 72 18 
24 0 0 60 15 
25 0 0 52 13 
26 0 0 36 9 
27 0 0 8 2 
28 0 0 4 1 
29 0 0 0 0 
30 0 0 0 0 
 
 Hence, the anatomopathological analysis 
demonstrated an overall tumor mass reduction in organs 
coming from treatment group. 
 Another observation was the different degrees of 
apoptosis present in most of the organs examined from 
the treated group, but in none of the control groups (Fig. 
2).  
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
New anti-cancer drugs rarely demonstrate 
themselves highly effective, and when they do, those 
good results are shown by using transplantable tumors in 
mice. These tumor models frequently involve human 
tumor xenografts in mice. Unfortunately, such preclinical 
results are often followed by failure of the drug/ therapy in 
clinical trials, since most of the effects obtained were due 
to the immunogenicity provoked by the xenografts. As a 
result, a shift has occurred in scientific studies towards 
using spontaneous mouse tumors arising in mice, in order 
to avoid that reaction. 
In vivo anti-tumor activity of WO2015001045 A2 
(PCT/ EP2014/ 064243) peptide was demonstrated in 
some human tumor lines when cells were transferred to 
the mice model. However, the results obtained in these 
assays might be biased by the immunogenic murine 
response to a strange cell exposure. A spontaneous 
murine tumor like “LB” T leukemia developed in BALB/ c 
mice helped our team dispel these doubts.  
In this trial, we demonstrated that the peptide 
administration statistics improved the overall mice’ 
survival affected by T leukemia when compared to non-
treated specimens. It also reduced the tumor mass in 
treated animals. Although at the very end all the mice died 
and the results obtained seemed to be scanty when 
compared to peptides inoculated to other tumors, it should 
be considered that LB leukemia is a very aggressive 
tumor that leads to the 100% death of the specimens 
affected, and, because of that, no treatment demonstrated 
Fig. 1 Survival analysis according to group of treatment 
 
A 
A 
B 
Fig. 2 Apoptosis Analysis of tumors cells after peptide’s 
treatment compared to control group TUNEL + apoptotic 
cells in the lymph node at 48 hours of 5 days of treatment. 
Apoptotic (yellow) cells were observed per high-
magnification 400X field in the different treatment groups. 
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efficacy so far. Besides, an improvement in the survival 
average rate of mice inoculated with LB T cells that 
received peptides (24.0 days vs. 11.5 days) had been 
shown. Taking into account the rapid aggressiveness 
after tumor injection, it could be logical to consider that 
peptide treatment should start before that day 5 in order to 
improve the results obtained even more. 
Conclusion 
This study demonstrated an improvement in the 
survival curves in the mice model affected by 
spontaneous lymphoid leukemia when peptides 
WO2015001045 A2 (PCT/ EP2014/ 064243) are used, in 
order to induce apoptosis in that type of tumor. Animals 
treated duplicated their survival rate and showed 440 
percentage of tumor reduction. Since the LB leukemia 
model used is a spontaneous tumor from BALB/ c mice, 
the possibility of immunogenicity involvement in the tumor 
control, is ruled out, and since the groups of mice treated 
were exactly obtained from the same endogamy batch of 
mice, the results were entirely explained by the new 
treatment administrated. 
These peptides can be a valid option to become 
part of the therapeutic armory for malignant aggressive T 
lymphoid-proliferative diseases control.  
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